Evidence map›Paper›PMID 36080254›Full record

ArticleMolecules (Basel, Switzerland)2022

Application of Af4-Multidetection to Liraglutide in Its Formulation: Preserving and Representing Native Aggregation.

Valentina Marassi, Marco Macis, Stefano Giordani, Lucia Ferrazzano, Alessandra Tolomelli, Barbara Roda, Andrea Zattoni, Antonio Ricci, Pierluigi Reschiglian, Walter Cabri

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Liraglutide-Conjugated Poly(methyl vinyl ether-ACS applied materials & interfaces · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Valentina MarassiDepartment of Chemistry G. Ciamician, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-8742-3708
Marco MacisFresenius Kabi iPSUM, Via San Leonardo 26, 45010 Villadose, Italy.
Stefano GiordaniDepartment of Chemistry G. Ciamician, University of Bologna, 40126 Bologna, Italy.
Lucia FerrazzanoDepartment of Chemistry G. Ciamician, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-7083-2211
Alessandra TolomelliDepartment of Chemistry G. Ciamician, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0003-4202-1136
Barbara RodaDepartment of Chemistry G. Ciamician, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0003-1060-2921
Andrea ZattoniDepartment of Chemistry G. Ciamician, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-6971-5360
Antonio RicciFresenius Kabi iPSUM, Via San Leonardo 26, 45010 Villadose, Italy.
Pierluigi ReschiglianDepartment of Chemistry G. Ciamician, University of Bologna, 40126 Bologna, Italy.
Walter CabriDepartment of Chemistry G. Ciamician, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-7865-0474
University of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aggregation is among the most critical parameters affecting the pharmacological and safety profile of peptide Active Pharmaceutical Ingredients (APIs). For this reason, it is of utmost importance to define the exact aggregation state of peptide drugs, particularly when the API is marketed as a ready-to-use solution. Consequently, appropriate non-destructive techniques able to replicate the peptide environment must be employed. In our work, we exploited Asymmetrical Flow Field-Flow Fractionation (AF4), connected to UV, dRI, fluorescence, and MALS detectors, to fully characterize the aggregation state of Liraglutide, a peptide API used for the treatment of diabetes type 2 and chronic obesity. In previous studies, Liraglutide was hypothesized to assemble into hexa-octamers in phosphate buffer, but no information on its behavior in the formulation medium was provided up to now. The method used allowed researchers to work using formulation as the mobile phase with excellent recoveries and LoQ/LoD, discerning between stable and degraded samples, and detecting, when present, aggregates up to 10

Indexed as

Fractionation, Field FlowLiraglutideLiraglutideactive pharmaceutical ingredient (API)FFF-multidetectionfinished dosage form (FDF)flow-field flow fractionationLiraglutidenative aggregation statereference listed drugRLDsamenesstherapeutic peptides

Identifiers

PMID36080254
PMCPMC9457993
OpenAlexW4293761098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.